Search

Kurt Fernstrom

Examiner (ID: 5518, Phone: (571)272-4422 , Office: P/3711 )

Most Active Art Unit
3711
Art Unit(s)
3714, 3712, 3715, 3711
Total Applications
2669
Issued Applications
1756
Pending Applications
157
Abandoned Applications
755

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18339973 [patent_doc_number] => 20230131922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => LONG-ACTING POLYPEPTIDE COMPOSITION FOR TREATING ATRIAL FIBRILLATION AND ITS APPLICATION [patent_app_type] => utility [patent_app_number] => 17/931117 [patent_app_country] => US [patent_app_date] => 2022-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17931117 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/931117
Long-acting polypeptide composition for treating atrial fibrillation and its application Sep 9, 2022 Issued
Array ( [id] => 18530336 [patent_doc_number] => 20230235406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE [patent_app_type] => utility [patent_app_number] => 17/903700 [patent_app_country] => US [patent_app_date] => 2022-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17903700 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/903700
IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE Sep 5, 2022
Array ( [id] => 18361105 [patent_doc_number] => 20230142696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => Reconstituted HDL Formulation [patent_app_type] => utility [patent_app_number] => 17/902580 [patent_app_country] => US [patent_app_date] => 2022-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17902580 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/902580
Reconstituted HDL formulation Sep 1, 2022 Issued
Array ( [id] => 18449618 [patent_doc_number] => 20230190894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => METHODS FOR TREATING PULMONARY DISEASE USING INTER-ALPHA INHIBITOR PROTEINS [patent_app_type] => utility [patent_app_number] => 17/821713 [patent_app_country] => US [patent_app_date] => 2022-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14119 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821713 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/821713
METHODS FOR TREATING PULMONARY DISEASE USING INTER-ALPHA INHIBITOR PROTEINS Aug 22, 2022 Pending
Array ( [id] => 18018170 [patent_doc_number] => 20220369669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => METHOD FOR PRODUCING HYDROLYSED KERATINACEOUS MATERIAL [patent_app_type] => utility [patent_app_number] => 17/879291 [patent_app_country] => US [patent_app_date] => 2022-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7584 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17879291 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/879291
METHOD FOR PRODUCING HYDROLYSED KERATINACEOUS MATERIAL Aug 1, 2022 Pending
Array ( [id] => 18321902 [patent_doc_number] => 20230120030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => Long-Acting Adrenomedullin Derivatives [patent_app_type] => utility [patent_app_number] => 17/816173 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816173 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/816173
Long-Acting Adrenomedullin Derivatives Jul 28, 2022 Abandoned
Array ( [id] => 18286300 [patent_doc_number] => 20230101772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => PEPTIDES AND METHODS FOR TREATING DISEASE [patent_app_type] => utility [patent_app_number] => 17/810513 [patent_app_country] => US [patent_app_date] => 2022-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810513 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/810513
PEPTIDES AND METHODS FOR TREATING DISEASE Jun 30, 2022 Pending
Array ( [id] => 17897050 [patent_doc_number] => 20220306712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => METHODS OF TREATMENT USING MUTANT FGF-21 PEPTIDE CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/842143 [patent_app_country] => US [patent_app_date] => 2022-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 219 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842143 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/842143
Methods of treatment using mutant FGF-21 peptide conjugates Jun 15, 2022 Issued
Array ( [id] => 17958659 [patent_doc_number] => 20220339239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY [patent_app_type] => utility [patent_app_number] => 17/831887 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831887 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/831887
USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY Jun 2, 2022 Pending
Array ( [id] => 18124145 [patent_doc_number] => 20230009757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => COMBINATION THERAPY FOR C3 INHIBITION [patent_app_type] => utility [patent_app_number] => 17/719074 [patent_app_country] => US [patent_app_date] => 2022-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17719074 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/719074
COMBINATION THERAPY FOR C3 INHIBITION Apr 11, 2022 Pending
Array ( [id] => 17850550 [patent_doc_number] => 20220280591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => Use For JNK Inhibitor Molecules For Treatment Of Various Diseases [patent_app_type] => utility [patent_app_number] => 17/719068 [patent_app_country] => US [patent_app_date] => 2022-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17719068 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/719068
Use For JNK Inhibitor Molecules For Treatment Of Various Diseases Apr 11, 2022 Abandoned
Array ( [id] => 17776563 [patent_doc_number] => 20220242912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => THERAPEUTIC PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/717982 [patent_app_country] => US [patent_app_date] => 2022-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717982 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/717982
Therapeutic peptides Apr 10, 2022 Issued
Array ( [id] => 18036587 [patent_doc_number] => 20220380802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => CYCLIN G1 INHIBITORS AND RELATED METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/713809 [patent_app_country] => US [patent_app_date] => 2022-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17713809 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/713809
CYCLIN G1 INHIBITORS AND RELATED METHODS OF TREATING CANCER Apr 4, 2022 Pending
Array ( [id] => 18004956 [patent_doc_number] => 20220363722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => Peptides for the Treatment of COVID-19 [patent_app_type] => utility [patent_app_number] => 17/699792 [patent_app_country] => US [patent_app_date] => 2022-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13106 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699792 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/699792
Peptides for the treatment of COVID-19 Mar 20, 2022 Issued
Array ( [id] => 17685901 [patent_doc_number] => 20220193193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING SLIT2 [patent_app_type] => utility [patent_app_number] => 17/682454 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682454 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/682454
METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING SLIT2 Feb 27, 2022 Pending
Array ( [id] => 18642361 [patent_doc_number] => 11766414 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Compositions, delivery systems, and methods useful in tumor therapy [patent_app_type] => utility [patent_app_number] => 17/577270 [patent_app_country] => US [patent_app_date] => 2022-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 64 [patent_no_of_words] => 40715 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 240 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17577270 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/577270
Compositions, delivery systems, and methods useful in tumor therapy Jan 16, 2022 Issued
Array ( [id] => 18871230 [patent_doc_number] => 11859018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Peptoid-based chelating ligands for selective metal chelation [patent_app_type] => utility [patent_app_number] => 17/576577 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 10956 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576577 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/576577
Peptoid-based chelating ligands for selective metal chelation Jan 13, 2022 Issued
Array ( [id] => 17546706 [patent_doc_number] => 20220118047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => METHOD OF TREATING GLIOBLASTOMA [patent_app_type] => utility [patent_app_number] => 17/563532 [patent_app_country] => US [patent_app_date] => 2021-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17563532 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/563532
METHOD OF TREATING GLIOBLASTOMA Dec 27, 2021 Pending
Array ( [id] => 19439982 [patent_doc_number] => 12090208 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Peptide drug improvement using vitamin B [patent_app_type] => utility [patent_app_number] => 17/558920 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 3824 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17558920 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/558920
Peptide drug improvement using vitamin B Dec 21, 2021 Issued
Array ( [id] => 18273713 [patent_doc_number] => 11612634 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance [patent_app_type] => utility [patent_app_number] => 17/548717 [patent_app_country] => US [patent_app_date] => 2021-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 47 [patent_no_of_words] => 12417 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548717 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/548717
Pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance Dec 12, 2021 Issued
Menu